Skip to main content
. 2013 Oct 30;15(5):R172. doi: 10.1186/ar4359

Figure 1.

Figure 1

Primary endpoint of the study EULAR Sjögren’s syndrome disease activity index in the rituximab and disease-modifying anti-rheumatic drug treatment groups. Primary endpoint of the study EULAR Sjögren’s syndrome disease activity index (ESSDAI) in the rituximab (RTX) and the disease-modifying anti-rheumatic drug (DMARD) treatment groups. Bars in the line charts indicate mean ± standard error of the mean. *P < 0.05, comparison between the two treatment arms at the corresponding time point.